Claudia Ordonez is Chief Medical Officer at Keros Therapeutics, Inc. (KROS). They have made 1 open-market trade across 1 company since 2021, most recently 2021-06-11.
CIK 0001808290
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KROS | 347 | $4K |
Shares reported on the most recent Form 4, priced at the 2021-06-15 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KROS | SELL · 10b5-1 | 2021-06-11 | 2021-06-15 | $50.99 | $51K | -13.3% | -23.6% | -40.3% |
| KROS | SELL | 2021-05-11 | 2021-05-13 | $50.15 | $50K | +9.4% | +14.4% | -25.0% |
| KROS | SELL · 10b5-1 | 2021-04-12 | 2021-04-14 | $59.93 | $60K | +3.7% | -20.6% | -35.4% |
| KROS | SELL · 10b5-1 | 2021-03-11 | 2021-03-15 | $64.56 | $65K | -7.4% | -3.8% | -17.3% |
| KROS | SELL · 10b5-1 | 2021-02-11 | 2021-02-16 | $64.84 | $65K | +9.2% | -8.3% | -15.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.